Bal Pharma Limited

To,
The Manager-Listing **3.12.2018**
National Stock Exchange of India Ltd
Mumbai.

The Manager-Listing
BSE Limited
Mumbai.

Dear Sir,

Ref : Disclosure as per Regulation 30 of SEBI(LODR) Regulations.

With reference to the above, we would like to inform the exchange that after obtaining all the regulatory approvals, our bulk drugs manufacturing unit at Udaipur has commenced its commercial production of intermediates and Active Pharma Ingredients (API).

The API products which of scheduled to be manufactured at this Unit were developed by our R&D facility at Bangalore and due to capacity constraints at our Bangalore facility they could not become commercially viable till now.

This unit is expected to ease the capacity concerns of API's and intermediates and will cater to the North are Northeastern markets of the country and also overseas markets.

To recapitulate, we have acquired 100% share holding and management control of Golden Drugs Pvt Ltd, Udaipur, Rajasthan , which is into manufacturing of API's and intermediates, during March 2018.

Please take this intimation on record.

Thanking You.

For Bal Pharma Ltd

Shailesh Siroya
Managing Director

CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India
Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58
Email : info@balpharma.com Website : www.balpharma.com
CIN # L85110KA1987PLC008368
REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph: 41570813 / 19 Fax: 41570820